Luke Devey – Biography
Last update: March 13, 2026Executive profile
Luke was Vice President, Head of Translational Science, Immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson, and Executive Director, Head of Early Discovery Biology at Celgene. Luke Devey joined Syncona in 2025.
Luke Devey is currentlyChief Medical Officer at Quell Therapeutics - View - Quell Therapeutics org chart
Venture Partner, Therapeutics at SV Health Investors - View - SV Health Investors org chart
Create your alert
to follow the career of Luke Devey.
Education
Luke Devey has a Master of Arts in Physiological Sciences from University of Oxford in 1995 and a PhD in Medicine from University of Birmingham in 2007.
They have also studied at University of Oxford :
Find more alumni from University of Oxford
They have also studied at University of Birmingham :
Find more alumni from University of Birmingham
More about Luke Devey
Selected links
Do you need to know more about Luke Devey? More results.
Participate
Social media
- Luke Devey on Google News, X (Twitter), LinkedIn, YouTube
- View the pictures of Luke Devey
The colleagues of Luke Devey
Company Colleagues
- At Quell Therapeutics, Luke Devey has 23 colleagues including Iain McGill (CEO & Director), Robert Lechler (Director)…
- At SV Health Investors, Luke Devey has 65 colleagues including Eugene Hill (Chairman of the Board), Paul LaViolette (COO & Medical Technology)…
Industry Colleagues
- In the Biotechnology industry, Luke Devey has 35,756 colleagues in 2,406 companies located in 42 countries. 16,877 executive movements have been recorded in the last 12 months. Learn more about Biotechnology.
Get in Touch
Here are a few tips for establishing great contacts.
and ask for Luke Devey.
